$331 Million is the total value of RTW INVESTMENTS, LP's 36 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| DRNA | Dicerna Pharmaceuticals Inc | $11,918,000 | +96.0% | 2,026,894 | 0.0% | 3.60% | +73.3% | |
| BMY | Bristol-Myers Squibb Co | $11,307,000 | -26.7% | 209,701 | 0.0% | 3.42% | -35.2% | |
| GLD | SPDR Gold Trust | $10,428,000 | -0.7% | 83,000 | 0.0% | 3.15% | -12.1% | |
| MASI | Masimo Corp | $1,541,000 | +13.3% | 25,900 | 0.0% | 0.47% | +0.2% | |
| BPMX | Biopharmx Corp | $389,000 | -14.5% | 700,636 | 0.0% | 0.12% | -23.9% | |
| NTRA | Natera Inc | $352,000 | -7.9% | 31,693 | 0.0% | 0.11% | -19.1% | |
| MNKD | MANNKIND CORPput | $272,000 | -70.2% | 4,385 | 0.0% | 0.08% | -73.7% | |
| NVLS | Nivalis Therapeutics Inc | $244,000 | +76.8% | 30,000 | 0.0% | 0.07% | +57.4% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2016-11-18
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS INC | 36 | Q3 2023 | 19.7% |
| MASIMO CORP | 32 | Q3 2023 | 5.8% |
| LA JOLLA PHARMACEUTICAL CO | 31 | Q2 2022 | 9.7% |
| REGENXBIO INC | 30 | Q4 2022 | 10.8% |
| AGENUS INC | 29 | Q2 2022 | 9.0% |
| PTC THERAPEUTICS INC | 28 | Q3 2023 | 12.8% |
| DICERNA PHARMACEUTICALS INC | 28 | Q3 2021 | 10.8% |
| MIRATI THERAPEUTICS INC | 26 | Q3 2023 | 6.2% |
| ARGENX SE | 26 | Q3 2023 | 5.3% |
| VERICEL CORP | 24 | Q3 2023 | 3.9% |
View RTW INVESTMENTS, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | September 19, 2023 | 18,188,457 | - |
| ALLURION TECHNOLOGIES, INC. | August 11, 2023 | 3,457,707 | 7.4% |
| Orchestra BioMed Holdings, Inc. | May 05, 2023 | 5,620,645 | 15.7% |
| Renovacor, Inc.Sold out | April 05, 2023 | 0 | - |
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Aptevo Therapeutics Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ASLAN Pharmaceuticals LtdSold out | February 14, 2023 | 0 | 0.0% |
| Athira Pharma, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| BELLUS Health Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Clearside Biomedical, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View RTW INVESTMENTS, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13D/A | 2024-04-17 |
| SC 13D/A | 2024-03-01 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View RTW INVESTMENTS, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.